The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate how therapeutic modulation of the apoptotic pathway may improve patient outcomes.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Jonathan D. Schoenfeld, MD, MPhil, MPH
Associate Professor of Radiation Oncology
Harvard Medical School
Senior Physician, Dana-Farber Cancer Institute
Director of Head and Neck Radiation Oncology
Brigham and Women’s Hospital
Dr. Schoenfeld has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: ACI Clinical, Castle Biosciences, Debiopharm, EMD Serono, Immunitas, LEK, Merck KGaA, SIRPant, Stimit
Ownership: Doximity, Immunitas
Research: Bristol Myers Squibb, EMD Serono, Merck, Regeneron
Robert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Professor of Otolaryngology, Immunology, and Radiation Oncology
University of Pittsburgh Medical Center
Dr. Ferris has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Adagene Incorporated, Adaptimmune, Aduro Biotech, Inc., Bicara Therapeutics, Inc., Bristol Myers Squibb, Catenion, Coherus BioSciences, Inc., CureVac, CytoAgents, Eisai Europe Limited, EMD Serono, Eterna Therapeutics, Everest Clinical Research Corporation, F. Hoffmann-La Roche Ltd., Federation Bio, Inc., Genmab, Genocea Biosciences, Inc., Hookipa Biotech GmbH, Instil Bio, Inc., Kowa Research Institute, Inc., Lifescience Dynamics Limited, MacroGenics, Inc., MeiraGTx, LLC, Mirati Therapeutics, Inc., Mirror Biologics, Inc., Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, PPD Development LP, Rakuten Medical, Inc., Regeneron, Sanofi, Seagen, Inc., SIRPant Immunotherapeutics, Inc., Vir Biotechnology, Inc., Zymeworks, Inc.
Ownership Interest: Novasenta
Research: AstraZeneca, Bristol Myers Squibb, Novasenta, Tesaro
- Jorge Bacigalupo has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Barry Fiedel, PhD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Describe unmet needs in the treatment of locally advanced carcinoma of the head and neck (LA SCCHN)
- Explain how modulation of apoptotic pathways can improve patient outcomes in LA SCCHN
This activity is designed to meet the educational needs of medical oncologists, radiation oncologists, oncology nurses, and advanced practice providers treating patients with head and neck cancers.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until December 22, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.
AGILE – Academy for Global InterprofessionalLearning andEducation – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.
This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this materialis not permitted without written permission from the copyright owner.
Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?1.00 program credit
Yelena Janjigian, MD
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD